|
A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer Clinical research trials and A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer clinical trial. Subjects frequently get the best healthcare possible for their A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer  A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
For Condition: Carcinoma, Non-Small-Cell Lung,Pancreatic Neoplasms,Colorectal Neoplasms,Breast Neoplasms
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients who are at least 18 years or older who have pathological or histological confirmation of colorectal, nonsmall-cell lung, breast or pancreas cancer. - No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast and no prior chemotherapy for pancreas cancer. - Original or recent tumor tissue must be available. - Patients must have been off prior chemotherapy for 4 weeks and radiation for 3 weeks. - Patients must have adequate renal, liver and bone marrow function, not have serious infection or life-threatening illness (unrelated to tumor). - Must be able to swallow capsules and not have gastrointestinal disorders that may affect absorption of the drug.
Total Enrollment: 172
Location and Contact Information:
Cedars-Sinai Comprehensive Cancer Center
Los Angeles, California, 90048-1804
United States
263 Wallace Tumor Institute
Birmingham, Alabama, 35294
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
Oncology Hematology Care, Inc
Cincinnati, Ohio, 45236
United States
UCLA School of Medicine
Los Angeles, California, 90095
United States
Harper Hospital
Detroit, Michigan, 48201
United States
Additional Information:
Study ID Numbers: 1040-000-002;
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034827
Other Pancreatic Neoplasms Studies:
1. Phase I-II study to evaluate safety, efficacy and pharmacokinetic interactions between capecitabine (XELODA) and exisulind (APTOSYN) in patients with metastatic breast cancer.
2. Positron Emission Tomography in Patients with Breast Cancer
3. Sequential Vaccinations in Combination with Standard Adjuvant Chemotherapy in High-Risk Breast Cancer Patients Following Surgical Treatment
4. A Phase 2 study of ET-743 in subjects with advanced breast cancer
5. Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
Related Studies:
Other Pancreatic Neoplasms Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
|
|
|
|
|
|
|
|
